Adalimumab Biosimilar Drug Aliquot | Anti-TNF-α | Therapeutic Antibody

Aliquoted from the biosimilar drug | Now available for research use

Aliquots of the biosimilar Adalimumab (Idacio®) are now available as research consumables.

Adalimumab biosimilar drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Adalimumab Biosimilar Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Idacio® / Adalimimab Biosimilar Drug

Drug nameIdacio®
INNAdalimimab biosimilar
API typeAdalimumab is a biosimilar medicinal product. Is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.
Pharmacotherapeutic groupImmunosuppressants, Tumour Necrosis Factor alpha (TNFα) inhibitors
ATC codeL04AB04
Target of antibodyTNFα
General functionAdalimumab is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. Also indicate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration.
Original license holder
Marketing authorisation numbersEU/1/19/1356/001
Marketing authorisation holderFresenius Kabi Deutschland GmbH
Else-Kröner-Straße 1
61352 Bad Homburg v. d. Höhe
Name of the manufacturer of the biological active substanceMerck Serono S.A.
Succursale de Corsier-sur-Vevey
Chemin du Fenil
Zone Industrielle B
1804 Corsier-sur-Vevey
Switzerland
Name and address of the manufacturer(s) responsible for batch releaseFresenius Kabi Austria GmbH
Hafnerstraße 36,
8055 Graz
Austria
Max shelf life24 months
Storage conditions2°C – 8°C
List of excipientsSodium dihydrogen phosphate dihydrate
Disodium phosphate dihydrate
Mannitol
Sodium chloride
Citric acid monohydrate
Sodium citrate
Polysorbate 80
Sodium hydroxide (for pH adjustment)
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting